{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T04:09:16Z","timestamp":1792642156295,"version":"4.5.0"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","award":["62\/086,077"],"award-info":[{"award-number":["62\/086,077"]}],"id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008497","name":"Boston Scientific Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008497","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004374","name":"Medtronic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004374","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007660","name":"Universiteit Antwerpen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007660","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001316","name":"Abbott Laboratories","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001316","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004411","name":"Heart and Stroke Foundation of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004411","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009550","name":"Universiteit Hasselt","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009550","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000145","name":"Alberta Innovates - Health Solutions","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000145","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002736","name":"Covidien","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002736","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007497","name":"Biosense Webster","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007497","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002973","name":"Daiichi-Sankyo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005035","name":"Biotronik","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005035","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.ahj.2017.12.007","type":"journal-article","created":{"date-parts":[[2017,12,8]],"date-time":"2017-12-08T13:35:48Z","timestamp":1512740148000},"page":"124-132","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":90,"special_numbering":"C","title":["The Optimal Anti-Coagulation for Enhanced-Risk Patients Post\u2013Catheter Ablation for Atrial Fibrillation (OCEAN) trial"],"prefix":"10.1016","volume":"197","author":[{"given":"Atul","family":"Verma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew C.T.","family":"Ha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulus","family":"Kirchhof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Hindricks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff S.","family":"Healey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mukul","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. George","family":"Wyse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Champagne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vidal","family":"Essebag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Wells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhiraj","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hein","family":"Heidbuchel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prashanthan","family":"Sanders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David H.","family":"Birnie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ahj.2017.12.007_bb0005","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1161\/CIRCEP.109.856633","article-title":"Pulmonary vein isolation for the maintenance of sinus rhythm in patients with atrial fibrillation: a meta-analysis of randomized, controlled trials","volume":"2","author":"Piccini","year":"2009","journal-title":"Circ Arrhythm Electrophysiol"},{"issue":"1","key":"10.1016\/j.ahj.2017.12.007_bb0010","first-page":"60","article-title":"Canadian Cardiovascular Society atrial fibrillation guidelines 2010: catheter ablation for atrial fibrillation\/atrial flutter","volume":"27","author":"Verma","year":"2011","journal-title":"Can J Cardiol"},{"issue":"38","key":"10.1016\/j.ahj.2017.12.007_bb0015","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","volume":"37","author":"Kirchhof","year":"2016","journal-title":"Eur Heart J"},{"issue":"10","key":"10.1016\/j.ahj.2017.12.007_bb0020","doi-asserted-by":"crossref","first-page":"e275","DOI":"10.1016\/j.hrthm.2017.05.012","article-title":"2017 HRS\/EHRA\/ECAS\/APHRS\/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation","volume":"14","author":"Calkins","year":"2017","journal-title":"Heart Rhythm"},{"issue":"23","key":"10.1016\/j.ahj.2017.12.007_bb0025","first-page":"e199","article-title":"2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society","volume":"130","author":"January","year":"2014","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.ahj.2017.12.007_bb0030","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1093\/europace\/eut162","article-title":"Ten-year trends in the use of catheter ablation for treatment of atrial fibrillation vs. the use of coronary intervention for the treatment of ischaemic heart disease in Australia","volume":"15","author":"Kumar","year":"2013","journal-title":"Europace"},{"issue":"19","key":"10.1016\/j.ahj.2017.12.007_bb0035","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1161\/CIRCULATIONAHA.113.003862","article-title":"In-hospital complications associated with catheter ablation of atrial fibrillation in the united states between 2000 and 2010: analysis of 93 801 procedures","volume":"128","author":"Deshmukh","year":"2013","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.ahj.2017.12.007_bb0045","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1161\/CIRCULATIONAHA.106.641225","article-title":"Risk of thromboembolic events after percutaneous left atrial radiofrequency ablation of atrial fibrillation","volume":"114","author":"Oral","year":"2006","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.ahj.2017.12.007_bb0050","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2459\/JCM.0b013e32801462d4","article-title":"Role of anticoagulation therapy after pulmonary vein antrum isolation for atrial fibrillation treatment","volume":"9","author":"Rossillo","year":"2008","journal-title":"J Cardiovasc Med (Hagerstown)"},{"issue":"9","key":"10.1016\/j.ahj.2017.12.007_bb0055","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1111\/j.1540-8167.2009.01481.x","article-title":"Warfarin is not needed in low-risk patients following atrial fibrillation ablation procedures","volume":"20","author":"Bunch","year":"2009","journal-title":"J Cardiovasc Electrophysiol"},{"issue":"8","key":"10.1016\/j.ahj.2017.12.007_bb0060","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.jacc.2009.11.039","article-title":"The risk of thromboembolism and need for oral anticoagulation after successful atrial fibrillation ablation","volume":"55","author":"Themistoclakis","year":"2010","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.ahj.2017.12.007_bb0065","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1161\/CIRCEP.111.963231","article-title":"Very low risk of thromboembolic events in patients undergoing successful catheter ablation of atrial fibrillation with a CHADS2 score \u22643: a long-term outcome study","volume":"4","author":"Saad","year":"2011","journal-title":"Circ Arrhythm Electrophysiol"},{"issue":"10","key":"10.1016\/j.ahj.2017.12.007_bb0070","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1253\/circj.CJ-11-0065","article-title":"Incidence of late thromboembolic events after catheter ablation of atrial fibrillation","volume":"75","author":"Yagishita","year":"2011","journal-title":"Circ J"},{"issue":"1","key":"10.1016\/j.ahj.2017.12.007_bb0075","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1540-8167.2011.02141.x","article-title":"Anticoagulant therapy and risk of cerebrovascular events after catheter ablation of atrial fibrillation in the elderly","volume":"23","author":"Guiot","year":"2012","journal-title":"J Cardiovasc Electrophysiol"},{"issue":"3","key":"10.1016\/j.ahj.2017.12.007_bb0080","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s10840-013-9835-1","article-title":"Discontinuing anticoagulation following successful atrial fibrillation ablation in patients with prior strokes","volume":"38","author":"Winkle","year":"2013","journal-title":"J Interv Card Electrophysiol"},{"issue":"7","key":"10.1016\/j.ahj.2017.12.007_bb0085","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1093\/europace\/eut406","article-title":"Incidence of cerebral thromboembolic events during long-term follow-up in patients treated with transcatheter ablation for atrial fibrillation","volume":"16","author":"Gaita","year":"2014","journal-title":"Europace"},{"issue":"1","key":"10.1016\/j.ahj.2017.12.007_bb0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/HCO.0000000000000121","article-title":"Long-term oral anticoagulation for patients after successful catheter ablation of atrial fibrillation: is it necessary?","volume":"30","author":"Ha","year":"2015","journal-title":"Curr Opin Cardiol"},{"issue":"8","key":"10.1016\/j.ahj.2017.12.007_bb0095","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1111\/j.1540-8167.2012.02381.x","article-title":"Venice Chart international consensus document on atrial fibrillation ablation: 2011 update","volume":"23","author":"Raviele","year":"2012","journal-title":"J Cardiovasc Electrophysiol"},{"issue":"5","key":"10.1016\/j.ahj.2017.12.007_bb0100","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.115.001901","article-title":"Catheter ablation of atrial fibrillation in U.S. community practice\u2014results From Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)","volume":"4","author":"Holmqvist","year":"2015","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"10.1016\/j.ahj.2017.12.007_bb0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40262-013-0100-7","article-title":"Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban","volume":"53","author":"Mueck","year":"2014","journal-title":"Clin Pharmacokinet"},{"issue":"7","key":"10.1016\/j.ahj.2017.12.007_bb0110","doi-asserted-by":"crossref","first-page":"549","DOI":"10.5414\/CP201812","article-title":"The effect of food on the absorption and pharmacokinetics of rivaroxaban","volume":"51","author":"Stampfuss","year":"2013","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"9","key":"10.1016\/j.ahj.2017.12.007_bb0115","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1253\/circj.CJ-12-0454","article-title":"Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation\u2014the J-ROCKET AF study","volume":"76","author":"Hori","year":"2012","journal-title":"Circ J"},{"issue":"10","key":"10.1016\/j.ahj.2017.12.007_bb0120","first-page":"1170","article-title":"2016 focused update of the Canadian Cardiovascular Society guidelines for the management of atrial fibrillation","volume":"32","author":"Macle","year":"2016","journal-title":"Can J Cardiol"},{"issue":"3","key":"10.1016\/j.ahj.2017.12.007_bb0125","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.ahj.2009.11.025","article-title":"Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation: rationale and design of the ROCKET AF study","volume":"159","author":"ROCKET AF study investigators","year":"2010","journal-title":"Am Heart J"},{"issue":"2","key":"10.1016\/j.ahj.2017.12.007_bb0130","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1161\/STROKEAHA.110.594754","article-title":"Wide variation in definition, detection, and description of lacunar lesions on imaging","volume":"42","author":"Potter","year":"2011","journal-title":"Stroke"},{"issue":"8","key":"10.1016\/j.ahj.2017.12.007_bb0135","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/S1474-4422(13)70124-8","article-title":"Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration","volume":"12","author":"Wardlaw","year":"2013","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.1016\/j.ahj.2017.12.007_bb0140","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1538-7836.2009.03678.x","volume":"8","author":"Schulman","year":"2010","journal-title":"J Thromb Haemost"},{"issue":"11","key":"10.1016\/j.ahj.2017.12.007_bb0145","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1111\/jth.13140","article-title":"Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH","volume":"13","author":"Kaatz","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"11","key":"10.1016\/j.ahj.2017.12.007_bb0150","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1093\/europace\/eut232","article-title":"Personalized management of atrial fibrillation: proceedings from the Fourth Atrial Fibrillation Competence NETwork\/European Heart Rhythm Association Consensus Conference","volume":"15","author":"Kirchhof","year":"2013","journal-title":"Europace"},{"issue":"6","key":"10.1016\/j.ahj.2017.12.007_bb0155","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1161\/STROKEAHA.108.192218","article-title":"Definition and evaluation of transient ischemic attack","volume":"40","author":"Easton","year":"2009","journal-title":"Stroke"},{"issue":"2","key":"10.1016\/j.ahj.2017.12.007_bb0160","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1161\/CIRCOUTCOMES.111.963108","article-title":"Health outcomes with catheter ablation or antiarrhythmic drug therapy in atrial fibrillation: results of a propensity-matched analysis","volume":"5","author":"Reynolds","year":"2012","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"8","key":"10.1016\/j.ahj.2017.12.007_bb0165","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1161\/01.CIR.92.8.2178","article-title":"Silent cerebral infarction in patients with nonrheumatic atrial fibrillation. The Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators","volume":"92","author":"Ezekowitz","year":"1995","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2017.12.007_bb0170","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1056\/NEJMoa1007432","article-title":"Apixaban in patients with atrial fibrillation","volume":"364","author":"Connolly","year":"2011","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ahj.2017.12.007_bb0175","first-page":"219","article-title":"Anticoagulation management pre- and post-atrial fibrillation ablation: a survey of Canadian centres","volume":"29","author":"Mardigyan","year":"2013","journal-title":"Can J Cardiol"},{"issue":"5","key":"10.1016\/j.ahj.2017.12.007_bb0180","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1093\/europace\/eus105","article-title":"Periprocedural anticoagulation therapy for devices and atrial fibrillation ablation","volume":"14","author":"Lip","year":"2012","journal-title":"Europace"},{"issue":"7","key":"10.1016\/j.ahj.2017.12.007_bb0185","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1161\/STR.0b013e318296aeca","article-title":"An updated definition of stroke for the 21st century: a statement for healthcare professionals from the American Heart Association\/American Stroke Association","volume":"44","author":"Sacco","year":"2013","journal-title":"Stroke"},{"issue":"11","key":"10.1016\/j.ahj.2017.12.007_bb0190","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1001\/archinte.1990.00390220082016","article-title":"Epidemiologic features of asymptomatic cerebral infarction in patients with nonvalvular atrial fibrillation","volume":"150","author":"Feinberg","year":"1990","journal-title":"Arch Intern Med"},{"issue":"21","key":"10.1016\/j.ahj.2017.12.007_bb0195","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1016\/j.jacc.2013.05.074","article-title":"Prevalence of silent cerebral ischemia in paroxysmal and persistent atrial fibrillation and correlation with cognitive function","volume":"62","author":"Gaita","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"10.1016\/j.ahj.2017.12.007_bb0200","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1212\/WNL.54.9.1795","article-title":"Atrial fibrillation and the risk of cerebral white matter lesions","volume":"54","author":"De Leeuw","year":"2000","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.ahj.2017.12.007_bb0205","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1016\/j.jacc.2004.11.071","article-title":"Patients with atrial fibrillation and dense spontaneous echo contrast at high risk a prospective and serial follow-up over 12 months with transesophageal echocardiography and cerebral magnetic resonance imaging","volume":"45","author":"Bernhardt","year":"2005","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"10.1016\/j.ahj.2017.12.007_bb0210","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.echo.2005.01.028","article-title":"Patients at high risk with atrial fibrillation: a prospective and serial follow-up during 12 months with transesophageal echocardiography and cerebral magnetic resonance imaging","volume":"18","author":"Bernhardt","year":"2005","journal-title":"J Am Soc Echocardiogr"},{"issue":"5","key":"10.1016\/j.ahj.2017.12.007_bb0215","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1161\/STROKEAHA.107.498535","article-title":"Progression of white matter hyperintensities and incidence of new lacunes over a 3-year period: the leukoaraiosis and disability study","volume":"39","author":"Gouw","year":"2008","journal-title":"Stroke"},{"issue":"3","key":"10.1016\/j.ahj.2017.12.007_bb0220","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1159\/000341404","article-title":"Extensive white matter changes predict stroke recurrence up to 5 years after a first-ever ischemic stroke","volume":"34","author":"Melkas","year":"2012","journal-title":"Cerebrovasc Dis"},{"issue":"11","key":"10.1016\/j.ahj.2017.12.007_bb0225","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1136\/jnnp.2008.154104","article-title":"Age related white matter changes predict stroke death in long term follow-up","volume":"80","author":"Oksala","year":"2009","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"10.1016\/j.ahj.2017.12.007_bb0230","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/ana.10294","article-title":"Periventricular cerebral white matter lesions predict rate of cognitive decline","volume":"52","author":"De Groot","year":"2002","journal-title":"Ann Neurol"},{"issue":"5","key":"10.1016\/j.ahj.2017.12.007_bb0235","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/j.1600-0404.1997.tb00289.x","article-title":"Neuropsychological deficits in asymptomatic atrial fibrillation","volume":"96","author":"Farina","year":"1997","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.ahj.2017.12.007_bb0240","doi-asserted-by":"crossref","first-page":"b2477","DOI":"10.1136\/bmj.b2477","article-title":"Changes in white matter as determinant of global functional decline in older independent outpatients: three year follow-up of LADIS (leukoaraiosis and disability) study cohort","volume":"339","author":"Inzitari","year":"2009","journal-title":"BMJ"},{"issue":"17","key":"10.1016\/j.ahj.2017.12.007_bb0245","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1093\/eurheartj\/ehn341","article-title":"Atrial fibrillation in stroke-free patients is associated with memory impairment and hippocampal atrophy","volume":"29","author":"Knecht","year":"2008","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1016\/j.ahj.2017.12.007_bb0250","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1161\/STROKEAHA.106.477299","article-title":"Atrial fibrillation, stroke, and cognition: a longitudinal population-based study of people aged 85 and older","volume":"38","author":"Rastas","year":"2007","journal-title":"Stroke"},{"issue":"2","key":"10.1016\/j.ahj.2017.12.007_bb0255","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jstrokecerebrovasdis.2005.11.001","article-title":"Silent brain infarction and subcortical white matter lesions increase the risk of stroke and mortality: a prospective cohort study","volume":"15","author":"Bokura","year":"2006","journal-title":"J Stroke Cerebrovasc Dis"},{"issue":"11","key":"10.1016\/j.ahj.2017.12.007_bb0260","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1161\/STROKEAHA.110.594853","article-title":"Cerebral small vessel disease and risk of death, ischemic stroke, and cardiac complications in patients with atherosclerotic disease: the Second Manifestations of Arterial Disease\u2013Magnetic Resonance (SMART-MR) study","volume":"42","author":"Conijn","year":"2011","journal-title":"Stroke"},{"issue":"12","key":"10.1016\/j.ahj.2017.12.007_bb0265","doi-asserted-by":"crossref","first-page":"3293","DOI":"10.1161\/STROKEAHA.113.002174","article-title":"Burden and outcome of prevalent ischemic brain disease in a National Acute Stroke Registry","volume":"44","author":"Koton","year":"2013","journal-title":"Stroke"},{"issue":"12","key":"10.1016\/j.ahj.2017.12.007_bb0270","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1161\/01.CIR.0000057981.70380.45","article-title":"Atrial high rate episodes detected by pacemaker diagnostics predict death and stroke: report of the Atrial Diagnostics Ancillary Study of the MOde Selection Trial (MOST)","volume":"107","author":"Glotzer","year":"2003","journal-title":"Circulation"},{"issue":"21","key":"10.1016\/j.ahj.2017.12.007_bb0275","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1161\/CIRCULATIONAHA.113.007825","article-title":"Temporal relationship between subclinical atrial fibrillation and embolic events","volume":"129","author":"Brambatti","year":"2014","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.ahj.2017.12.007_bb0280","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1093\/europace\/euw279","article-title":"Atrial high-rate episodes and stroke prevention","volume":"19","author":"Camm","year":"2017","journal-title":"Europace"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870317303939?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870317303939?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T09:56:28Z","timestamp":1762077388000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870317303939"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":55,"alternative-id":["S0002870317303939"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2017.12.007","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Optimal Anti-Coagulation for Enhanced-Risk Patients Post\u2013Catheter Ablation for Atrial Fibrillation (OCEAN) trial","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2017.12.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}